Models for 10,000 Human Diseases

CRISPR Screen Identifies Potential New Regulators of Fibrosis in Human Liver Cells

In our last few liver articles, we highlighted the urgent need for new models and treatments for non-alcoholic steatohepatitis (NASH), and looked at the potential for human liver organoids to not only model disease, but also to test new drugs for safety and efficacy. Here, we dive into a recent study that identified novel potential mediators of liver fibrosis using a genome-wide CRISPR screen in primary human liver cells. Studies like this are a starting point towards understanding the mechanisms underlying liver fibrosis and will hopefully help to reveal new drug targets for NASH and other forms of liver fibrosis.  What causes liver fibrosis? What we know so far...  Liver...

Cell of the Month: Liver Sinusoidal Endothelial Cells

Liver sinusoidal endothelial cells (LSECs) are highly specialized liver endothelial cells that form a physical barrier between the blood and hepatocytes. They are the most abundant non-parenchymal hepatic cell population. LSECs play an important role in physiological,...

read more

Tempo-iMG™: Architectural Strategies

Tempo-iMG™ was cited in in a study that investigated HIV-1 integration in the unexplored microglia reservoir that gives rise to continued HIV replication in infected cells. Scientists used Tempo-iMG™ human iPSC-derived microglia to determine that CTCF, an...

read more

Tempo Bioscience Services

Disease Models and Assay Services

Tempo offers services and alliances based on our advanced technological platforms and a range of capabilities. Our team differentiates ourselves based on a strong commitment to innovative solutions and quality R&D for our partners.

Tempo Bioscience Support

On Demand Custom Engineered Cell Models

Tempo develops patient relevant stem cell (iPSCs) based models to support drug discovery, preclinical studies, and early-stage clinical development.